ABSTRACT
Prostate cancer is the second major cause of death among men due to cancer in North America. According to the Canadian Cancer Society, about 20,000 men are diagnosed with prostate cancer annually in Canada and about 4000 die from it [1]. The various methods for the treatment of prostate cancer [2] include surgical intervention, external radiotherapy, high-dose rate brachytherapy, cryotherapy (freezing therapy), RF (heat) therapy, and lowdose rate brachytherapy. The low-dose rate brachytherapy has proven to be effective and successful and, thus, has some advantages over surgical intervention because it does not cause impotence or incontinence that is associated with surgical intervention due to damage of tissues in close proximity with the prostate. In addition, it avoids the deleterious effects of external radiation on surrounding healthy tissues (e.g., seminal vesicles, essential nerve bundles, bladder, rectum, and the urethra).
